{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:14:47Z","timestamp":1794838487852,"version":"4.9.1"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T00:00:00Z","timestamp":1249344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fc receptor\u2010like 2 (FCRL2) is highly expressed on B\u2010cell chronic lymphocytic leukemia (B\u2010CLL) cells and could possibly influence disease pathogenesis. Therefore, we investigated FCRL2 mRNA expression in a large cohort with 152 CLL patients in order to assess its role in risk prediction in B\u2010CLL. FCRL2 mRNA expression was found to be expressed at considerably higher levels in peripheral blood mononuclear cells (PBMC) of B\u2010CLL patients compared to controls (range 1.35\u2010 to 210\u2010fold upregulation; <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001) and cells of other hematological diseases. Patients with high FCRL2 expression (according to ROC\u2010analysis) had a significantly longer treatment\u2010free survival (TFS) and overall survival (OS) than patients with low FCRL2 expression (median TFS: 119 vs. 34\u2003months, <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001; median OS: 321\u2003months vs. not reached, <jats:italic>P\u2003<\/jats:italic>=\u20030.009). Univariate comparisons found that FCRL2 expression was weakly associated with <jats:italic>IGHV<\/jats:italic> mutation status (<jats:italic>P\u2003<\/jats:italic>=\u20030.05), CD38 status (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001) and ZAP\u201070 status (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001). Furthermore, we show that the combination of FCRL2 with ZAP70\u2010, CD38\u2010 or IGHV\u2010status could further significantly refine the prognostic information provided by either of the factors alone in TFS and OS. In multivariate analysis low FCRL2 expression was a significant independent prognostic factor (HR 2.4; <jats:italic>P\u2003<\/jats:italic>=\u20030.005). Here we demonstrate that the level of FCRL2 expression is correlated with prognosis in B\u2010CLL.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2009.01328.x","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T04:27:55Z","timestamp":1249360075000},"page":"541-549","source":"Crossref","is-referenced-by-count":18,"title":["FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia"],"prefix":"10.1111","volume":"83","author":[{"given":"Holger","family":"N\u00fcckel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crista H.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich H.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Sellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00fcrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Siffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,11,10]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.399"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154070"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1023"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.181"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023143"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403147"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.133"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2683"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.11.1639"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040857"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403748"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500464161"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3306"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404363"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141541"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-131359"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402339"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2002-3-7-research0034"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403707"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1385\/IR:26:1-3:177"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/90935"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2003.09.006"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2009.01328.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2009.01328.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:04:00Z","timestamp":1697429040000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2009.01328.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,10]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1600-0609.2009.01328.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01328.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,10]]}}}